JP2021521230A - グルコース応答性インスリン - Google Patents

グルコース応答性インスリン Download PDF

Info

Publication number
JP2021521230A
JP2021521230A JP2020556885A JP2020556885A JP2021521230A JP 2021521230 A JP2021521230 A JP 2021521230A JP 2020556885 A JP2020556885 A JP 2020556885A JP 2020556885 A JP2020556885 A JP 2020556885A JP 2021521230 A JP2021521230 A JP 2021521230A
Authority
JP
Japan
Prior art keywords
insulin
peptide
chain
peptide according
lysine residue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020556885A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521230A5 (enExample
Inventor
ダニー ホン−ジェ チョウ
ダニー ホン−ジェ チョウ
Original Assignee
ユニヴァーシティー オブ ユタ リサーチ ファウンデーション
ユニヴァーシティー オブ ユタ リサーチ ファウンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニヴァーシティー オブ ユタ リサーチ ファウンデーション, ユニヴァーシティー オブ ユタ リサーチ ファウンデーション filed Critical ユニヴァーシティー オブ ユタ リサーチ ファウンデーション
Publication of JP2021521230A publication Critical patent/JP2021521230A/ja
Publication of JP2021521230A5 publication Critical patent/JP2021521230A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020556885A 2018-04-16 2019-04-15 グルコース応答性インスリン Pending JP2021521230A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862658372P 2018-04-16 2018-04-16
US62/658,372 2018-04-16
PCT/US2019/027484 WO2019204206A1 (en) 2018-04-16 2019-04-15 Glucose-responsive insulin

Publications (2)

Publication Number Publication Date
JP2021521230A true JP2021521230A (ja) 2021-08-26
JP2021521230A5 JP2021521230A5 (enExample) 2022-04-25

Family

ID=68239869

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020556885A Pending JP2021521230A (ja) 2018-04-16 2019-04-15 グルコース応答性インスリン

Country Status (8)

Country Link
US (1) US20210214412A1 (enExample)
EP (1) EP3781147A4 (enExample)
JP (1) JP2021521230A (enExample)
KR (1) KR20210005630A (enExample)
CN (1) CN112423741A (enExample)
AU (1) AU2019255611A1 (enExample)
CA (1) CA3097359A1 (enExample)
WO (1) WO2019204206A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025506650A (ja) * 2022-02-17 2025-03-13 レボロ バイオセラピューティクス リミテッド シャペロニン６０．１由来のペプチドを作製する方法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3291828A4 (en) 2015-05-06 2018-10-03 Alborz Mahdavi Glucose responsive insulins
WO2018107117A1 (en) 2016-12-09 2018-06-14 Akston Biosciences Corporation Insulin-fc fusions and methods of use
EP3707145B1 (en) 2017-11-09 2023-06-21 Novo Nordisk A/S Glucose-sensitive albumin-binding derivatives
CN113038964B (zh) 2018-06-29 2025-05-27 德克拉有限公司 超长效胰岛素-fc融合蛋白及使用方法
US11267862B2 (en) 2018-06-29 2022-03-08 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
JP7640462B2 (ja) * 2019-03-29 2025-03-05 ノヴォ ノルディスク アー／エス グルコース感受性インスリン誘導体
US20220288213A1 (en) * 2019-07-31 2022-09-15 Thermalin Inc. Insulin analogues with glucose regulated conformational switch
HUE064376T2 (hu) 2019-12-19 2024-03-28 Akston Biosciences Corp Ultra-hosszú hatású inzulin-FC fúziós fehérjék és felhasználási eljárások
US11186623B2 (en) 2019-12-24 2021-11-30 Akston Bioscience Corporation Ultra-long acting insulin-Fc fusion proteins and methods of use
CA3173417A1 (en) * 2020-03-31 2021-10-07 Alborz Mahdavi Conjugates for selective responsiveness to vicinal diols
US11192930B2 (en) 2020-04-10 2021-12-07 Askton Bioscences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
KR102898622B1 (ko) 2020-04-10 2025-12-12 악스톤 바이오사이언시스 코퍼레이션 Covid-19 융합 단백질에 대한 항원 특이적 면역요법 및 사용 방법
US11198719B2 (en) 2020-04-29 2021-12-14 Akston Biosciences Corporation Ultra-long acting insulin-Fc fusion protein and methods of use
PH12023500012A1 (en) * 2020-11-19 2024-03-11 Protomer Tech Inc Aromatic boron-containing compounds and insulin analogs
WO2023004406A2 (en) 2021-07-23 2023-01-26 Akston Biosciences Corporation Insulin-fc fusion proteins and methods of use to treat cancer
WO2023225534A1 (en) 2022-05-18 2023-11-23 Protomer Technologies Inc. Aromatic boron-containing compounds and related insulin analogs
WO2025117822A1 (en) * 2023-11-28 2025-06-05 University Of Notre Dame Du Lac Glucose-triggered gelation of supramolecular peptide nanocoils with glucose-binding motifs

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6070100A (ja) * 1983-09-26 1985-04-20 Wako Pure Chem Ind Ltd 新規ヒト型インシュリン誘導体，その製法，及びヒト型インシュリンの製造法
JP2005526009A (ja) * 2001-12-02 2005-09-02 ノボ　ノルディスク　アクティーゼルスカブ 新規グルコース依存性インスリン
US20090030178A1 (en) * 2006-08-02 2009-01-29 Phoenix Pharmaceuticals, Inc. Cell permeable bioactive peptide conjugates
JP2013520175A (ja) * 2010-02-22 2013-06-06 ケース ウェスタン リザーブ ユニバーシティ 可溶形および結晶形の長時間作用型インスリン類似体製剤
US20150320837A1 (en) * 2012-12-12 2015-11-12 Massachusetts Institute Of Technology Insulin derivatives for diabetes treatment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3837825A1 (de) * 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
US7317000B2 (en) * 2001-12-02 2008-01-08 Novo Nordisk A/S Glucose-dependent insulins
UA113626C2 (xx) * 2011-06-02 2017-02-27 Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії
US20160031962A1 (en) * 2012-04-20 2016-02-04 Kleomenis K. Barlos Solid phase peptide synthesis of insulin using side chain achored lysine
EP3291828A4 (en) * 2015-05-06 2018-10-03 Alborz Mahdavi Glucose responsive insulins

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6070100A (ja) * 1983-09-26 1985-04-20 Wako Pure Chem Ind Ltd 新規ヒト型インシュリン誘導体，その製法，及びヒト型インシュリンの製造法
JP2005526009A (ja) * 2001-12-02 2005-09-02 ノボ　ノルディスク　アクティーゼルスカブ 新規グルコース依存性インスリン
US20090030178A1 (en) * 2006-08-02 2009-01-29 Phoenix Pharmaceuticals, Inc. Cell permeable bioactive peptide conjugates
JP2013520175A (ja) * 2010-02-22 2013-06-06 ケース ウェスタン リザーブ ユニバーシティ 可溶形および結晶形の長時間作用型インスリン類似体製剤
US20150320837A1 (en) * 2012-12-12 2015-11-12 Massachusetts Institute Of Technology Insulin derivatives for diabetes treatment

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 112, no. 8, JPN6023014662, 2015, pages 2401 - 2406, ISSN: 0005036354 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025506650A (ja) * 2022-02-17 2025-03-13 レボロ バイオセラピューティクス リミテッド シャペロニン６０．１由来のペプチドを作製する方法

Also Published As

Publication number Publication date
EP3781147A1 (en) 2021-02-24
US20210214412A1 (en) 2021-07-15
WO2019204206A1 (en) 2019-10-24
KR20210005630A (ko) 2021-01-14
EP3781147A4 (en) 2022-04-20
CA3097359A1 (en) 2019-10-24
AU2019255611A1 (en) 2020-11-12
CN112423741A (zh) 2021-02-26

Similar Documents

Publication Publication Date Title
KR20210005630A (ko) 글루코스-반응성 인슐린
JP7490735B2 (ja) ジスルフィド含有細胞膜透過ペプチド並びにその製造方法及び使用方法
ES2238641T3 (es) Tiazolididas y pirrolididas de glutamina, asi como su utilizacion como agentes inhibidores de la dipeptidilpeptidasa iv.
DK2694095T3 (en) COMPOSITIONS COMPREHENSIVE GLUCAGON ANALOGS AND METHODS FOR PREPARING AND USING THE SAME
JP6581606B2 (ja) 選択的グルカゴン受容体アゴニストとしてのエキセンジン−４誘導体
CN103906756B (zh) 用于治疗疾病的方法
CN102421429B (zh) 癌症治疗用选择性ep4受体拮抗物质
JP2014520798A (ja) ポリエチレングリコールまたはその誘導体でｐｅｇ化されたエキセンジン−４類似体、その調製法、および活性成分としてこれを含有する、糖尿病を予防または処置するための薬学的組成物
US20190092724A1 (en) Cyano-substituted indole compounds and uses thereof as lsd1 inhibitors
CN103228655A (zh) 咔唑和咔啉衍生物，及其制备方法和治疗应用
CN103354757A (zh) 脂肪代谢障碍的治疗
US20110270151A1 (en) Image-guided energy deposition for targeted drug delivery
US11155577B2 (en) Thiol-ene based peptide stapling and uses thereof
TW202039437A (zh) 肽黏合劑
CN105801705A (zh) 含胰高血糖素样肽-1和免疫球蛋白杂合Fc的融合多肽及其用途
JP2019519478A (ja) ペプチド−オリゴ尿素フォルダマー化合物及びそれらの使用方法
CA3198757A1 (en) Aromatic boron-containing compounds and insulin analogs
KR20170066609A (ko) 인돌리논 화합물 및 이의 용도
KR20140097108A (ko) 전구약물로서의 펜타미딘 아미독심 산 에스테르류 및 이의 약물로서의 용도
CN106554404A (zh) 一种艾塞那肽修饰物及其用途
KR20090077935A (ko) 내당능 장애 관련 증상을 예방하거나 치료하기 위한 인간 ｅｐｏ 수용체 작용제, 조성물, 방법 및 용도
JP2016526533A (ja) アミリンミメティック化合物とポリエチレングリコールの非凝集バイオ接合体
TW202304883A (zh) 用於治療惡性實體腫瘤之吡唑基嘧啶
WO2022109066A1 (en) Compounds for the treatment of acute and chronic kidney disease
CA3008182A1 (en) Non-agglomerating bioconjugates of amylin and amylin-mimetic compounds, compositions comprising the same, and making and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220415

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220415

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230413

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231109